MRNA shot into tumors aims to rally immune system against cancer
NCT ID NCT07587879
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This early-stage study tests a new mRNA-based immunotherapy called PMC2129G12 for people with advanced solid tumors that have not responded to standard treatments. The treatment is injected directly into the tumor and is designed to help the body's immune cells attack the cancer. The main goals are to check safety and find the best dose, with a small look at whether it shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IntraAb Inc.
Richmond, California, 94806, United States
Conditions
Explore the condition pages connected to this study.